Willow Biosciences Inc - Asset Resilience Ratio

Latest as of March 2025: 0.86%

Willow Biosciences Inc (WLLW) has an Asset Resilience Ratio of 0.86% as of March 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check Willow Biosciences Inc PP&E and investment ratio to assess the company's strategic physical and investment asset allocation.

Liquid Assets

CA$20.00K

≈ $14.47K USD Cash + Short-term Investments

Total Assets

CA$2.31 Million

≈ $1.67 Million USD All company assets

Resilience Assessment

Low

Financial Resilience Level

Asset Resilience Ratio Trend (2015–2024)

This chart shows how Willow Biosciences Inc's Asset Resilience Ratio has changed over time. See WLLW equity to assets ratio to measure how much of total assets are equity-financed.

Liquid Assets Composition Over Time

This chart breaks down Willow Biosciences Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see market value of Willow Biosciences Inc.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	CA$0.00	0%
Short-term Investments	CA$20.00K	0.86%
Total Liquid Assets	CA$20.00K	0.86%

Asset Resilience Insights

Limited Liquidity: Willow Biosciences Inc maintains only 0.86% of assets in liquid form.
This low level may indicate efficient asset utilization but could pose risks during economic downturns.
The company has significant short-term investments, indicating active treasury management.

Willow Biosciences Inc Industry Peers by Asset Resilience Ratio

Compare Willow Biosciences Inc's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
Swedish Orphan Biovitrum AB (publ) ST:SOBI	Drug Manufacturers - Specialty & Generic	1.54%
Aurobindo Pharma Limited NSE:AUROPHARMA	Drug Manufacturers - Specialty & Generic	1.28%
Shijiazhuang Yiling Pharmaceutical Co Ltd SHE:002603	Drug Manufacturers - Specialty & Generic	11.60%
Shandong Buchang Pharmaceuticals Co Ltd SHG:603858	Drug Manufacturers - Specialty & Generic	3.47%
Tianjin Chase Sun Pharmaceutical Co Ltd SHE:300026	Drug Manufacturers - Specialty & Generic	-0.89%
Zhejiang Hisoar Pharmaceutical Co Ltd SHE:002099	Drug Manufacturers - Specialty & Generic	0.20%
Xeris Pharmaceuticals Inc NASDAQ:XERS	Drug Manufacturers - Specialty & Generic	0.00%
Procter & Gamble Health Limited NSE:PGHL	Drug Manufacturers - Specialty & Generic	33.01%

Annual Asset Resilience Ratio for Willow Biosciences Inc (2015–2024)

The table below shows the annual Asset Resilience Ratio data for Willow Biosciences Inc.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2024-12-31	0.80%	CA$20.00K ≈ $14.47K	CA$2.49 Million ≈ $1.80 Million	+0.50pp
2023-12-31	0.30%	CA$20.00K ≈ $14.47K	CA$6.67 Million ≈ $4.83 Million	-82.50pp
2022-12-31	82.80%	CA$15.03 Million ≈ $10.87 Million	CA$18.15 Million ≈ $13.13 Million	-5.15pp
2021-12-31	87.95%	CA$30.80 Million ≈ $22.28 Million	CA$35.02 Million ≈ $25.33 Million	+12.69pp
2020-12-31	75.27%	CA$16.46 Million ≈ $11.90 Million	CA$21.86 Million ≈ $15.82 Million	+16.75pp
2019-12-31	58.51%	CA$19.83 Million ≈ $14.34 Million	CA$33.88 Million ≈ $24.51 Million	+50.41pp
2016-12-31	8.10%	CA$137.61K ≈ $99.54K	CA$1.70 Million ≈ $1.23 Million	-7.42pp
2015-12-31	15.52%	CA$374.75K ≈ $271.09K	CA$2.42 Million ≈ $1.75 Million	--

pp = percentage points

About Willow Biosciences Inc

TO:WLLW Canada Drug Manufacturers - Specialty & Generic

Market Cap

$18.10 Million

CA$25.02 Million CAD

Market Cap Rank

#28516 Global

#1280 in Canada

Share Price

CA$0.17

Change (1 day)

+0.00%

52-Week Range

CA$0.03 - CA$0.32

All Time High

CA$2.08